• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Fractyl Health Inc.

    1/13/26 6:35:56 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care
    Get the next $GUTS alert in real time by email
    S-8 1 guts-20260113.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on January 13, 2026

     

     

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ______________

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ___________________

    Fractyl Health, Inc.

    (Exact name of registrant as specified in its charter)

    ___________________

     

     

     

     

     

     

    Delaware

    (State of incorporation or organization)

    27-3553477

    (I.R.S. Employer Identification No.)

    3 Van de Graaff Drive, Suite 200

    Burlington, MA

    (Address of principal executive office)

    01803

    (Zip Code)

     

    2024 Incentive Award Plan

    2024 Employee Stock Purchase Plan

    New Hire Inducement Stock Option Grant

    (Full title of the plan)

    Harith Rajagopalan, M.D., Ph.D.

    Chief Executive Officer

    Fractyl Health, Inc.

    3 Van de Graaff Drive, Suite 200

    Burlington, MA 01803

    (781) 902-8800

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

    Marc Recht

    James Schneider

    Cooley LLP

    500 Boylston Street, 14th Floor

    Boston, MA 02116

    (617) 937-2300

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

    Large Accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    We are filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “SEC”) for the purpose of registering (a) an additional 10,106,374 shares of our common stock (“Common Stock”) under our 2024 Incentive Award Plan (the “Incentive Plan”) and (b) an additional 2,021,274 shares of Common Stock under our 2024 Employee Stock Purchase Plan (the “ESPP”), pursuant to the provisions of the Incentive Plan and ESPP which provide for annual automatic increases in the number of shares of Common Stock reserved for issuance under the Incentive Plan and ESPP. Such shares of Common Stock represent the increases that occurred on January 1, 2025 and January 1, 2026 and are being registered in addition to the shares of Common Stock under the Incentive Plan and ESPP registered on our Registration Statement on Form S-8 (File No. 333-276897), filed with the SEC on February 6, 2024. (the “Prior Form S-8”).

    In addition, we are also filing this Registration Statement on Form S-8 to register 1,036,800 shares of Common Stock underlying an outstanding stock option award granted to Lara Smith Weber (the “Inducement Award”). Upon the recommendation of the Compensation and Human Strategy Committee of the Board of Directors (the “Board”), the Board granted the Inducement Award outside of our Incentive Plan as inducement for Ms. Smith Weber’s acceptance of employment as our Chief Financial Officer, in accordance with Nasdaq Listing Rule 5635(c)(4).

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

    PART II

    ITEM 3.

    INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE.

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8 are incorporated by reference herein. In addition, the following documents we filed with the SEC are incorporated by reference into this Registration Statement:

    (a) Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 3, 2025;

    (b) Our Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 13, 2025, for the quarterly period ended June 30, 2025, filed with the SEC on August 12, 2025 and for the quarterly period ended September 30, 2025, filed with the SEC on November 12, 2025;

    (c) Our Current Reports on Form 8-K filed with the SEC on January 31, 2025, March 13, 2025, April 1, 2025, June 12, 2025, June 18, 2025, June 23, 2025, August 7, 2025, September 3, 2025, September 26, 2025, September 26, 2025, October 3, 2025, December 2, 2025, December 16, 2025, January 5, 2026 and January 6, 2026 to the extent the information in such Current Reports is not furnished pursuant to Item 2.02 or Item 7.01 and exhibits furnished under Item 9.01 that relate to such items;

    (d) The description of our Common Stock, which is contained in our registration statement on Form 8-A, filed with the SEC on January 29, 2024 (File No. 001-41942) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description; and

    (e) All documents, reports and definitive proxy or information statements filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents, except as to any portion of any future annual or quarterly report to stockholders that is not deemed filed under such provisions of the Exchange Act or information furnished under Item 2.02 or Item 7.01 of Form 8-K or exhibits furnished under Item 9.01 on Form 8-K that relate to such items.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Current Report on Form 8-K expressly provides to the contrary.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently

     


     

    filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 8. EXHIBITS.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Incorporated by Reference

    Exhibit
    Number

    Description

    Schedule
    Form

    File Number

    Exhibit

    Filing Date

    3.1

    Amended and Restated Certificate of Incorporation of Fractyl Health, Inc.

    8-K

    001-41942

    3.1

    February 6, 2024

    3.2

    Amended and Restated Bylaws of Fractyl Health, Inc.

    8-K

    001-41942

    3.2

    February 6, 2024

    5.1*

    Opinion of Cooley LLP.

     

     

     

     

    23.1*

    Consent of Ernst & Young LLP, independent registered public accounting firm.

     

     

     

     

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

     

    24.1*

    Power of Attorney (included on the signature page of this Form S-8).

     

     

     

     

    99.1

    2024 Incentive Award Plan and forms of award agreements thereunder.

    10-K

    001-41942

    10.14

    April 1, 2024

    99.2

    2024 Employee Stock Purchase Plan.

    S-1/A

    333-276046

    10.16

    January 29, 2024

    99.3*

    Inducement Award Agreement between Fractyl Health, Inc. and Lara Smith Weber, dated January 12, 2026.

     

     

     

     

    107*

    Filing Fee Table

     

     

     

     

     

     

     

     

     

     

    *Filed herewith.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the town of Burlington, Commonwealth of Massachusetts on this 13th day of January, 2026.

    Fractyl Health, Inc.

    By: /s/ Harith Rajagopalan

    Harith Rajagopalan, M.D., Ph.D.
    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Harith Rajagopalan, M.D., Ph.D. and Lara Smith Weber, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Title

     

    Signature

     

    Date

     

     

     

     

     

    /s/ Harith Rajagopalan

     

    Co-Founder, Chief Executive Officer and Director

     

    January 13, 2026

    Harith Rajagopalan, M.D., Ph.D.

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Lara Smith Weber

     

    Chief Financial Officer and Treasurer

     

    January 13, 2026

    Lara Smith Weber

     

    (Principal Financial Officer and Principal Accounting Officer)

     

     

     

     

     

     

     

    /s/ Kelly Barnes

     

    Director

     

    January 13, 2026

    Kelly Barnes

     

     

     

     

     

     

     

     

     

    /s/ William W. Bradley

     

    Director

     

    January 13, 2026

    William W. Bradley

     

     

     

     

     

     

     

     

     

    /s/ Samuel Conaway

     

    Director

     

    January 13, 2026

    Samuel Conaway

     

     

     

     

     

     

     

     

     

    /s/Marc Elia

     

    Director

     

    January 13, 2026

    Marc Elia

     

     

     

     

     

     

     

     

     

    /s/ Clive Meanwell

     

    Director

     

    January 13, 2026

    Clive Meanwell, M.B., Ch.B., M.D.

     

     

     

     

     

     

     

     

     

    /s/ Christopher C. Thompson

     

    Director

     

    January 13, 2026

    Christopher C. Thompson, M.D., MSc

     

     

     

     

     

     

     

     

     

    /s/ Ajay Royan

     

    Chairman

     

    January 13, 2026

    Ajay Royan

     

     

     

     

     

     

     

     

     

    /s/ Ian Sheffield

     

    Director

     

    January 13, 2026

    Ian Sheffield

     

     

     

     

     

     


     

     

     


    Get the next $GUTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    9/15/2025$9.00Buy
    H.C. Wainwright
    8/28/2025$3.60Buy
    Ladenburg Thalmann
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fractyl Health downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Fractyl Health from Overweight to Equal-Weight and set a new price target of $2.00

    1/30/26 6:42:49 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Fractyl Health with a new price target

    H.C. Wainwright initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $9.00

    9/15/25 8:08:19 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on Fractyl Health with a new price target

    Ladenburg Thalmann initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $3.60

    8/28/25 8:09:13 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Smith Weber Lara

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:30:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Smith Weber Lara

    3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:15:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, Chief Product Off. Caplan Jay David

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/17/25 6:00:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)

    2/17/26 4:39:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)

    2/12/26 4:18:37 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    1/29/26 8:00:35 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

    BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company's executive leadership team and Board of Directors. Ms. Smith Weber brings more than 20 years of financial leadership experience across medtech, biotech, and other growth-oriented industries. She has a str

    1/6/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

    Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027 BURLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D)

    1/5/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rajagopalan Harith bought $19,999 worth of shares (10,416 units at $1.92), increasing direct ownership by 2% to 501,745 units (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/8/25 7:05:03 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 7:57:09 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 4:50:44 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Leadership Updates

    Live Leadership Updates

    View All

    Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

    BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

    4/2/24 8:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

    LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

    2/20/24 8:38:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Financials

    Live finance-specific insights

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company f

    11/5/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

    BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the conference call and presentatio

    8/6/25 4:05:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/14/24 4:30:50 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/13/24 5:17:27 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

    2/16/24 9:43:25 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care